Healthcare

In itsQuarterly Reportdated 30 October 2026, BCAL said clinical validation had been completed for BREASTESTplus 2 in women aged 30 and over across all breast densities, with launch targeted for November 2026. The company also said accreditation and operational activities were under way.

In itsQuarterly Reportfor the period ended 30 September 2026, Clarity said it held cash of $152.9 million to progress its programs. The Cohort Expansion of the Phase I/IIa SECuRE trial achieved its recruitment target in October 2026, with sixteen participants with metastatic castration-resistant prostate …

The company's November 2026 presentation sets out its StemSmart program and describes progress towards a new treatment for severe Crohn's disease. The presentation notes that it was prepared on information available at theDate of Issueand includes forward-looking statements, which carry risks and uncertainties.

In an ASX announcement dated 5 November 2026, Neuren said Q3 2026 DAYBUE net sales were US$140 million, up 39% from Q3 2025, driven by uptake of DAYBUE STIX. The company earned Q3 royalty income of US$16.4 million, up 51% from a year earlier.

• Greenbrook clinic revenue rose 20.1% to $26.2 million, reflecting continued expansion of the direct-care business.

• The trial targets patients with MTAP-deleted pancreatic cancer and MTAP-deleted/RAS mutant non-small cell lung cancer

• Total revenue reached $89.0 million, compared to $27.5 million in Q3 2025, a more than threefold increase